Immunotherapy with subcutaneous immunoglobulin or plasmapheresis in patients with postural orthostatic tachycardia syndrome (POTS).

This resource discusses a case series involving patients with severe POTS who were not responding to standard treatments. It explores the outcomes of using subcutaneous immunoglobulin (SCIG) therapy or plasmapheresis (PLEX) as treatments. The findings indicate that all patients showed improved symptoms, with reductions in autonomic symptoms and enhanced functional abilities, evidenced by improvements in COMPASS 31 and FAS scores. Most patients could reduce or stop their oral medications for POTS and return to work or school. The study suggests that immunotherapy may benefit treatment-resistant POTS patients and emphasizes the need for randomized controlled trials to evaluate the long-term efficacy and safety of SCIG and PLEX for these patients.